109 related articles for article (PubMed ID: 34281856)
1. A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
Yamanaka M; Hayashi M; Yamada S; Sonohara F; Takami H; Inokawa Y; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Koike M; Kodera Y
Anticancer Res; 2021 Aug; 41(8):3933-3940. PubMed ID: 34281856
[TBL] [Abstract][Full Text] [Related]
2. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
[TBL] [Abstract][Full Text] [Related]
3. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
Hosokawa Y; Nagakawa Y; Sahara Y; Takishita C; Katsumata K; Tsuchida A
Dig Surg; 2017; 34(2):125-132. PubMed ID: 27658221
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
5. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
[TBL] [Abstract][Full Text] [Related]
6. Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer.
Takagi C; Kikuchi Y; Shirakawa H; Hoshimoto S; Tomikawa M; Ozawa I; Hishinuma S; Ogata Y
Anticancer Res; 2019 Jun; 39(6):3177-3183. PubMed ID: 31177164
[TBL] [Abstract][Full Text] [Related]
7. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
8. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
9. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal adenocarcinoma.
Hashimoto D; Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Ishida M; Matsui Y; Shibata N; Boku S; Katsushima U; Ikeura T; Sekimoto M
Pancreatology; 2023 Jan; 23(1):73-81. PubMed ID: 36494309
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
13. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
[TBL] [Abstract][Full Text] [Related]
15. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
16. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
18. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
19. The concept of oligometastatic disease in gastric cancer: reality or fiction?
Kassar S; Samaha R; Aoun R; Khoury M; Kattan J
Future Oncol; 2022 Jan; 18(2):135-138. PubMed ID: 34889659
[TBL] [Abstract][Full Text] [Related]
20. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]